KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
You may also be interested in...
Morphine sulfate extended-release product’s approval with only one of three routes of abuse raises questions about how effectively US FDA’s policies are encouraging development of abuse-deterrent opioid formulations.
Company cites FDA 'confusion' and indicates it will drop the product without the claim.
FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.